1. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis 
Altacílio Aparecido Nunes, Anderson Soares da Silva, Kathiaja Miranda Souza, Christine de Nazaré Silva Koury, Luane Marques de Mello 
Critical Reviews in Oncology / Hematology 
Volume 94, Issue 3, Pages (June 2015)
DOI: /j.critrevonc
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Flowchart of selection of studies found and included for conducting meta-analysis.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Forest plot for standardized difference in mean time of PFS in the included studies. CLL patients treated with FC and FCR.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Forest plot of findings about the complete remission among patients receiving FC vs. FCR.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
Forest plot of findings about the OS time (in months) among patients receiving FC vs. FCR.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions